This company listing is no longer active
Henry Schein Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Henry Schein has been growing earnings at an average annual rate of 3.3%, while the Healthcare industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 7.3% per year. Henry Schein's return on equity is 9.2%, and it has net margins of 3.5%.
Belangrijke informatie
3.3%
Groei van de winst
5.9%
Groei van de winst per aandeel
Healthcare Groei van de industrie | 15.7% |
Inkomstengroei | 7.3% |
Rendement op eigen vermogen | 9.2% |
Nettomarge | 3.5% |
Laatste winstupdate | 30 Sep 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Henry Schein geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 23 | 12,693 | 445 | 2,898 | 0 |
01 Jul 23 | 12,598 | 458 | 2,833 | 0 |
01 Apr 23 | 12,528 | 478 | 2,806 | 0 |
31 Dec 22 | 12,647 | 538 | 2,771 | 0 |
24 Sep 22 | 12,607 | 638 | 2,732 | 0 |
25 Jun 22 | 12,718 | 650 | 2,747 | 0 |
26 Mar 22 | 12,655 | 646 | 2,702 | 0 |
25 Dec 21 | 12,401 | 631 | 2,634 | 0 |
25 Sep 21 | 12,236 | 626 | 2,581 | 0 |
26 Jun 21 | 11,898 | 606 | 2,484 | 0 |
27 Mar 21 | 10,615 | 438 | 2,294 | 0 |
26 Dec 20 | 10,119 | 403 | 2,086 | 0 |
26 Sep 20 | 9,622 | 591 | 2,188 | 0 |
27 Jun 20 | 9,291 | 585 | 2,203 | 0 |
28 Mar 20 | 10,054 | 713 | 2,351 | 0 |
28 Dec 19 | 9,986 | 701 | 2,358 | 0 |
28 Sep 19 | 9,789 | 488 | 2,301 | 0 |
29 Jun 19 | 9,636 | 444 | 2,278 | 0 |
30 Mar 19 | 9,504 | 438 | 2,238 | 0 |
29 Dec 18 | 9,418 | 431 | 2,217 | 0 |
29 Sep 18 | 10,263 | 304 | 2,319 | 0 |
30 Jun 18 | 11,069 | 352 | 2,384 | 0 |
31 Mar 18 | 11,812 | 377 | 2,460 | 0 |
30 Dec 17 | 8,883 | 293 | 2,072 | 0 |
30 Sep 17 | 12,264 | 554 | 2,504 | 0 |
01 Jul 17 | 11,968 | 550 | 2,468 | 0 |
01 Apr 17 | 11,782 | 534 | 2,440 | 0 |
31 Dec 16 | 11,572 | 507 | 2,409 | 0 |
24 Sep 16 | 11,302 | 498 | 2,366 | 0 |
25 Jun 16 | 11,122 | 492 | 2,336 | 0 |
26 Mar 16 | 10,879 | 489 | 2,296 | 0 |
26 Dec 15 | 10,630 | 479 | 2,238 | 0 |
26 Sep 15 | 10,481 | 482 | 2,219 | 0 |
27 Jun 15 | 10,419 | 469 | 2,215 | 0 |
28 Mar 15 | 10,405 | 467 | 2,202 | 0 |
27 Dec 14 | 10,371 | 466 | 2,196 | 0 |
27 Sep 14 | 10,196 | 457 | 2,147 | 0 |
28 Jun 14 | 9,921 | 450 | 2,079 | 0 |
29 Mar 14 | 9,697 | 442 | 2,025 | 0 |
28 Dec 13 | 9,561 | 432 | 1,979 | 0 |
28 Sep 13 | 9,443 | 420 | 1,948 | 0 |
29 Jun 13 | 9,325 | 409 | 1,929 | 0 |
30 Mar 13 | 9,134 | 399 | 1,901 | 0 |
Kwaliteitswinsten: HS2 has a large one-off loss of $192.0M impacting its last 12 months of financial results to 30th September, 2023.
Groeiende winstmarge: HS2's current net profit margins (3.5%) are lower than last year (5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: HS2's earnings have grown by 3.3% per year over the past 5 years.
Versnelling van de groei: HS2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: HS2 had negative earnings growth (-29.6%) over the past year, making it difficult to compare to the Healthcare industry average (-16.1%).
Rendement op eigen vermogen
Hoge ROE: HS2's Return on Equity (9.2%) is considered low.